FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Calquence combination approved in EU for 1L MCL
06 May 2025
Calquence plus chemoimmunotherapy approved in the
EU
as first and only BTK inhibitor for 1st-line mantle cell
lymphoma
Approval based on ECHO Phase III trial results which demonstrated
over 16 months of progression-free survival improvement vs.
chemoimmunotherapy alone
AstraZeneca's Calquence (acalabrutinib) in combination with
bendamustine and rituximab has been approved in the European Union
(EU) for the treatment of adult patients with previously
untreated mantle cell lymphoma (MCL) who are not eligible for
autologous stem cell transplant.
The approval by the European Commission follows
the positive
opinion of the Committee
for Medicinal Products for Human Use and was based on positive
results from ECHO Phase III
trial, presented at the
European Haematology Association (EHA) 2024 Congress and published
in The
Journal of Clinical Oncology,
which demonstrated that Calquence plus
bendamustine and rituximab reduced the risk of disease progression
or death by 27% compared to standard-of-care chemoimmunotherapy
(hazard ratio [HR] 0.73; 95% confidence interval [CI] 0.57-0.94;
p=0.016). Median progression-free survival (PFS) was 66.4 months
for patients treated with the Calquence combination
versus 49.6 with chemoimmunotherapy alone.
MCL is a rare and typically aggressive form of non-Hodgkin
lymphoma, often diagnosed at an advanced stage.1,2 An
estimated 6,000 patients were diagnosed with MCL in the UK, France,
Germany, Spain and Italy in 2024.3
Martin Dreyling, MD, Department of Medicine, University Hospital
LMU Munich, and investigator in the trial, said: "This approval
provides a new first-line treatment option for patients in the EU
with mantle cell lymphoma, an aggressive lymphoma with a dismal
long-term outcome still today. With a progression-free survival
improvement of more than 16 months for these patients, the
acalabrutinib combination is a much-needed advance in this
challenging disease."
Dave Fredrickson, Executive Vice President, Oncology Haematology
Business Unit, AstraZeneca, said: "Treatment with
the Calquence combination in first-line mantle cell
lymphoma demonstrated a significant improvement in progression free
survival and a consistent safety profile for patients in the
pivotal ECHO trial. As the first and only BTK inhibitor approved in
this indication in the EU, we are proud to provide a much-needed
new option to patients living with this difficult
disease."
The safety and tolerability of Calquence was consistent with its known safety
profile, and no new safety signals were
identified.
Calquence plus
bendamustine and rituximab is approved in the US and several other
countries in this setting based on the ECHO results. Regulatory
applications are currently under review in Japan and several other
countries in this indication.
This approval follows the recent approval
for Calquence monotherapy for the treatment of adult
patients with relapsed or refractory MCL in the
EU.
Notes
Mantle cell lymphoma (MCL)
While MCL patients initially respond to treatment, patients do tend
to relapse.4 MCL
comprises about 3-6% of non-Hodgkin lymphomas, with an annual
incidence of 0.5 per 100,000 population in Western countries; It is
estimated that there are more than 21,000 patients diagnosed with
MCL in the US, UK, France, Germany, Spain, Italy, Japan and
China.3,4,5
ECHO
ECHO is a randomised, double-blind, placebo-controlled,
multi-centre Phase III trial evaluating the efficacy and safety
of Calquence plus bendamustine and rituximab compared to
SoC chemoimmunotherapy (bendamustine and rituximab) in adult
patients at or over 65 years of age (n=635) with previously
untreated MCL.6 Patients
were randomised 1:1 to receive either Calquence or placebo administered orally twice per
day, continuously, until disease progression or unacceptable
toxicity. Additionally, all patients received six 28-day cycles of
bendamustine on days 1 and 2 and rituximab on day 1 of each cycle,
followed by rituximab maintenance for two years if patients
achieved a response after induction therapy.6
The primary endpoint is PFS assessed by an Independent Review
Committee; other efficacy endpoints include overall survival (OS),
overall response rate, duration of response and time to
response.6 The
trial was conducted in 27 countries across North and South America,
Europe, Asia and Oceania.6
The ECHO trial enrolled patients from May 2017 to March 2023,
continuing through the COVID-19 pandemic. Prespecified PFS and OS
analyses censoring for COVID-19 deaths were conducted to assess the
impact of COVID-19 on the study outcome in alignment with the
FDA.
Calquence
Calquence is a
second-generation, selective inhibitor of Bruton's tyrosine kinase
(BTK). Calquence binds
covalently to BTK, thereby inhibiting its
activity.7 In
B-cells, BTK signalling results in activation of pathways necessary
for B-cell proliferation, trafficking, chemotaxis and
adhesion.
Calquence is approved for
the treatment of chronic lymphocytic leukaemia (CLL) and small
lymphocytic lymphoma (SLL) in the US, Japan and China, and approved
for CLL in the EU and many other countries. Calquence is
also approved for the treatment of adult patients with previously
untreated MCL in the US and other countries. It is also approved
for the treatment of adult patients with MCL who have received at
least one prior therapy in China and several other
countries. Calquence is
not currently approved for the treatment of MCL in
Japan.
As part of an extensive clinical development
programme, Calquence is currently being evaluated as a single
treatment and in combination with standard-of-care
chemoimmunotherapy for patients with multiple B-cell blood cancers,
including CLL, MCL and diffuse large B-cell
lymphoma.
AstraZeneca in haematology
AstraZeneca is pushing the boundaries of science to redefine care
in haematology. Our goal is to help transform the lives of patients
living with malignant, rare and other related haematologic diseases
through innovative medicines and approaches that are shaped by
insights from patients, caregivers and
physicians.
In addition to our marketed products, we are spearheading the
development of novel therapies designed to target underlying
drivers of disease across multiple scientific platforms. Our
acquisitions of Alexion, with expertise in rare, non-malignant
blood disorders, and Gracell Biotechnologies Inc., pioneers of
autologous cell therapies, expand our haematology pipeline and
enable us to reach more patients with high unmet needs through the
end-to-end discovery, development and delivery of novel
therapies.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition
to provide cures for cancer in every form, following the science to
understand cancer and all its complexities to discover, develop and
deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It
is through persistent innovation that AstraZeneca has built one of
the most diverse portfolios and pipelines in the industry, with the
potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1. Lymphoma Research
Foundation. Mantle Cell Lymphoma. Available at: https://lymphoma.org/aboutlymphoma/nhl/mcl/.
Accessed April 2025.
2. National Organization for Rare
Disorders. Mantle Cell Lymphoma. Available
at: https://rarediseases.org/rare-diseases/mantle-cell-lymphoma/.
Accessed April 2025.
3. AstraZeneca 2024. Q3 2024 Financial
Results. Available at: https://www.astrazeneca.com/investor-relations.html.
Accessed April 2025.
4. Cheah C, Seymour J, Wang ML. Mantle
cell lymphoma. J Clin
Oncol. 2016;34(11):1256-1269.
doi: 10.1200/JCO.2015.63.5904.
5. Lynch DT, Koya S, Acharya U, et al.
Mantle Cell Lymphoma. Available at: https://www.ncbi.nlm.nih.gov/books/NBK536985/.
Accessed April 2025.
6.
ClinicalTrials.gov. A Study of BR Alone Versus in Combination With
Acalabrutinib in Subjects With Previously Untreated MCL. Available
at: https://clinicaltrials.gov/study/NCT02972840. Accessed
April 2025.
7. Wu J, et al. Acalabrutinib
(ACP-196): a selective second-generation BTK
inhibitor. J Hematol
Oncol.
2016;9(21).
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
06 May 2025
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|